[Clinical significance of survivin expression in peripheral T-cell lymphoma].
OBJECTIVE
Peripheral T-cell lymphoma (PTCL) accounts for about 10%-15% of non-hodgkin's lymphomas (NHL), usually associated with short clinical course and poor prognosis. The over expression of survivin, a member of inhibitor of apoptotic protein (IAP), is regarded as a poor prognostic index in many malignant tumors. This study was to detect the expression of survivin in PTCL, and analyze its correlation to clinical features and prognosis of PTCL.


METHODS
The expression of survivin in 51 specimens of naive PTCL was detected by immunohistochemistry. The correlations of survivin expression to clinical features and prognosis were analyzed by SPSS10.0 software.


RESULTS
The positive rate of survivin was 82.3%. Its expression had no significant correlations to sex, age, clinical stage, the number of extranodal lesions, performance status, serum level of lactate dehydrogenase, B symptoms, and international prognostic index (P>0.05). The 5-year overall survival rate of the 51 patients was 32.67%. The patients with positive survivin expression had poorer 5-year overall survival than negative patients (25.0% vs. 75.0%, P=0.03). Cox regression model showed that survivin was an independent poor prognostic index of PTCL.


CONCLUSIONS
Survivin is a useful prognostic index of PTCL. We can screen out the cases which may have poor prognosis early by combining survivin expression with IPI, and improve the treatment outcome of PTCL.
Xiang
Xiao-Juan
XJ
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China. xxjwen@163.com
He
You-Jian
YJ
Li
Yu-Hong
YH
Huang
He
H
Xu
Fei
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D015996:Survival Rate; D000077022:Survivin; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone